Biology and genetics

Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02. Leleu X et al. Blood. 2015 Jan 9. pii: blood-2014-11-612069. [Epub ahead of print]. The predominant myeloma clone at diagnosis, CDR3 defined, is constantly detectable across all stages of disease evolution. Puig N et al. Leukemia. 2015 Jan 8. doi: 10.1038/leu.2015.7. [Epub ahead of print]. Combined immune checkpoint protein blockade…

Supportive care

Plasmapheresis in cast nephropathy: yes or no? Madore F. Curr Opin Nephrol Hypertens. 2015 Jan 14. [Epub ahead of print]. Antimicrobial peptides: an alternative for innovative medicines? da Costa JP et al. Appl Microbiol Biotechnol. 2015 Jan 15. [Epub ahead of print]. Outcomes following surgical intervention for impending and gross instability caused by multiple myeloma in the spinal column. Zadnik PL et al. J…

General

Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting. Arroz M et al. Cytometry B Clin Cytom. 2015 Jan 23. doi: 10.1002/cyto.b.21228. [Epub ahead of print]. Novel agents have a significant impact on survival of patients with multiple myeloma. Lamm W et al. Wien Klin Wochenschr. 2015 Jan 22. [Epub ahead of print]. Multiple myeloma. Mehta A. Hematology. 2015 Jan;20(1):58-9. doi: 10.1179/1024533214Z.000000000333.…

Complications of myeloma and its treatments

Pleural effusion formation in the course of myeloma. Comert M etal. Arch Bronconeumol. 2015 Jan 22. pii: S0300-2896(14)00242-7. doi: 10.1016/j.arbres.2014.05.009. [Epub ahead of print]. Diagnosis of monoclonal gammopathy of renal significance. Bridoux F et al. Kidney Int. 2015 Jan 21. doi: 10.1038/ki.2014.408. [Epub ahead of print]. Paralytic ileus following “subcutaneous bortezomib” therapy: focus on the clinical emergency-report of two cases. Mele…

Current treatments

An open label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin and dexamethasone in newly diagnosed myeloma. Nishihori T et al. Eur J Haematol. 2015 Jan 20. doi: 10.1111/ejh.12509. [Epub ahead of print]. A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myelomanot eligible for or who deferred autologous stem cell transplantation.…

Diagnostic tests and prognostic indicators

Heavy/Light Chain Assay for Monitoring IgA Multiple Myeloma: Digging Out the IgA from the β Region. Calderon B et al. Clin Chem. 2014 Dec 10. pii: clinchem.2014.234757. [Epub ahead of print]. Dysregulated class I histone deacetylases are indicators of poor prognosis in multiple myeloma. Mithraprabhu S et al. Epigenetics. 2014 Dec 6:0. [Epub ahead of print]. Calorimetric markers of bence jones and nonsecretory multiple…

Related conditions

Smoldering multiple myeloma: special considerations surrounding treatment on versus off clinical trials. Manasanch EE et al. Haematologica. 2014 Dec;99(12):1769-71. doi: 10.3324/haematol.2014.107516. Disseminated sclerotic bone lesions with normal 18F-FDG uptake in POEMS syndrome. Shi X et al. Leuk Lymphoma. 2014 Dec 2:1-9. [Epub ahead of print]. Monoclonal gammopathy of renal significance with light-chain deposition disease diagnosed postrenal transplant: a diagnostic and therapeutic challenge.…

Emerging treatments

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma. Stewart AK et al. N Engl J Med. 2014 Dec 6. [Epub ahead of print]. Phase I/II study exploring ImMucin, a pan-major histocompatibility complex, anti-MUC1 signal peptide vaccine, inmultiple myeloma patients. Carmon L et al. Br J Haematol. 2014 Dec 11. doi: 10.1111/bjh.13245. [Epub ahead of print]. The potential role of PD0332991 (Palbociclib) in the…

Biology and genetics

Curcumin induces cell death of the main molecular myeloma subtypes, particularly the poor prognosis subgroups. Gomez-Bougie P et al. Cancer Biol Ther. 2014 Dec 17:0. [Epub ahead of print]. Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Nijhof IS et al. Haematologica. 2014 Dec 15. pii: haematol.2014.117531. [Epub ahead of print]. Doxorubicin Overcomes Resistance…